Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations
December 7, 2020
62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
Area of Focus
Oncology
Programs
IRAKIMiD (KT-413)
Indications
MYD88 Tumors
Development Stage
Pre-clinical Data
Share
